Oxford Nanopore Technologies is set to partner with Geneyx for the development of a scalable software solution for use in nanopore sequencing.

The new software solution is being developed for the end-to-end analysis and clinical reporting of nanopore sequencing data.

Hospitals, genetic labs and researchers can use the new advanced platform to collect data and analyse human whole-genome sequencing.

Expected to be available after the completion of a pilot phase, the new software platform will mainly focus on accelerating the clinical use of nanopore sequencing besides loading, visualising and interpreting nanopore sequencing data.

The platform will be initially used for newborn screening, as well as the research and characterisation of rare and undiagnosed diseases.

According to Oxford Nanopore, the software is anticipated to offer a "one-click" analysis of whole human sequencing data, including useful genetic variants.   

Oxford Nanopore CEO Gordon Sanghera said: “We are excited to collaborate with Geneyx to develop an end-to-end analysis tool for the clinical reporting of nanopore sequencing data.”

Under the collaboration, Geneyx’s data analysis capabilities will be combined with Oxford Nanopore’s human-variation workflow and secure data transfer.

The platform will be integrated with Oxford Nanopore’s data analysis solution, EPI2ME, to conduct the secondary sequence analysis.

The results will then be sent to the Geneyx cloud and on-site capability for accurate annotation and variants classification. It will help offer simplified bioinformatics for future clinical applications.

The partnership will begin with pilot projects to assess the platform within third-party sites. At present, the Geneyx solution is used by 4,000 active users in 36 countries across the world.

Geneyx CEO David Yizhar said: “This collaboration combines Geneyx’s analysis expertise with Oxford Nanopore Technologies' groundbreaking sequencing technology.”